Update shared on15 Aug 2025
Karyopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92.
What's in the News
- Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.
- Added to Russell Microcap Value Benchmark Index.
- Added to Russell 3000E Value Benchmark.
- Added to Russell Microcap Value Index.
- Added to Russell 3000E Value Index.
Valuation Changes
Summary of Valuation Changes for Karyopharm Therapeutics
- The Consensus Analyst Price Target remained effectively unchanged, at $25.92.
- The Net Profit Margin for Karyopharm Therapeutics has significantly risen from 13.98% to 15.95%.
- The Future P/E for Karyopharm Therapeutics has significantly fallen from 7.81x to 6.85x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.